




To Improve Lives
by Transforming
Robotic Surgery





Disclaimer

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to recognize the benefits of Vicarious Surgical’s business combination, which may be affected by, among other things, competition and its ability to grow and manage growth profitably and retain its key employees; the ability to maintain the listing of Vicarious Surgical’s Class A common stock on the New York Stock Exchange; the success, cost and timing of Vicarious Surgical’s product and service development activities; the commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of Vicarious Surgical’s single-port surgical robot, called the Vicarious Surgical System, and any of Vicarious Surgical’s future product candidates and service offerings; the potential attributes and benefits of the the Vicarious Surgical System and any of Vicarious Surgical’s other product and service offerings once commercialized; Vicarious Surgical’s ability to obtain and maintain regulatory authorization for the the Vicarious Surgical System and its product and service offerings, and any related restrictions and limitations of any authorized product or service offering; changes in U.S. and foreign laws; Vicarious Surgical’s ability to identify, in license or acquire additional technology; Vicarious Surgical’s ability to maintain its license agreements and manufacturing arrangements; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services for use in ventral hernia repair procedures and additional surgical applications; the size and growth potential of the markets for the the Vicarious Surgical System and any of Vicarious Surgical’s future product and service offerings, and its ability to serve those markets once commercialized, either alone or in partnership with others; Vicarious Surgical’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Vicarious Surgical’s ability to raise financing in the future; Vicarious Surgical’s financial performance; Vicarious Surgical’s intellectual property rights and how failure to protect or enforce these rights could harm its business, results of operations and financial condition; economic downturns and political and market conditions beyond the control of Vicarious Surgical and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; the anticipated continued impact of the COVID-19 pandemic on Vicarious Surgical’s business; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

All surgical images contained within this presentation are sourced from cadaveric procedures.



The Worlds Most Advanced Surgical Robot



First Surgical Robot Designed for General Surgery

Re-invented robotic surgery leveraging proprietary decoupled actuators for enhanced ease of use, clinical outcomes and economics across the highest volume surgical procedures



A Decade of R&D - Ready for First Human Use in Late 2025

Fortified manufacturing capabilities and integrated supply chain, with the team and process for execution at scale




We Are Backed By Top-Tier Partners

Attracted world's largest surgical robotics customer - HCA, 6 hospital systems, and leading investors - Khosla, Gates, Innovation Endeavors, and E15



Our Journey

Leveraging over a decade of R&D and \$300 million of investment.





Extensive Market Opportunity

Large initial market opportunity with
96% whitespace.^{1,2}

\$150 Billion

INITIAL MARKET OPPORTUNITY:

- Hernia
- Gallbladder
- Gastrointestinal
- Gynecology


45 Million

PROCEDURES ABDOMINAL ROBOTIC-
ADDRESSABLE WORLDWIDE PER YEAR



96% Manual

~4 ROBOTIC ADOPTION DUE TO:




- High cost & low contribution margin
- Limited access & capability
- Difficulty of use & training



Existing Robots Are Designed for Prostate Surgery¹⁰

One of the lowest volume (yet highest margin) standard abdominal procedures.



Data collected from a center of excellence partner hospital system.



A History of Surgery

1846

1987

1999

2014

Vicarious
Surgical

Open Surgery



- ✗ Manual procedure
- ✗ Single large incision
- ✓ Whole abdomen access (any quadrant, any approach)
- ✓ Easy set-up

Laparoscopic Surgery



- ✗ Manual procedure
- ~ Multi-small incision
- ✗ Partial abdomen access (one quadrant per setup)
- ~ Moderate set-up

Robotic/Laparoscopic

HIGH ACUITY & HIGH COST	Intuitive
SUPPORTS STAPLER & VESSEL SEALER BUSINESS	Medtronic JNJ
LOW COST ALTERNATIVE	CMR Distalmotion

- ✓ Robotic procedure
- ~ Multi-small incision
- ✗ Partial abdomen access (one quadrant per setup)
- ~ Complex set-up

First Gen Single Port



- ✓ Robotic procedure
- ✗ Single large incision
- ✗ Partial abdomen access (one quadrant, one approach)
- ~ Moderate set-up

Next Gen Single Port




- ✓ Robotic procedure
- ✓ Single small incision
- ✓ Whole abdomen access (any quadrant, any approach)
- ✓ Easy set-up



The Vicarious Surgical Benefit


Patient Outcomes

One Small Incision – Just 1.8cm^{3,4}



Simplicity & Maneuverability Inside the Abdomen

Yesterday's Multi-Port



Roboticized Laparoscopy

4 degrees of freedom per arm through multiple incisions leads to:

- Complex training for incision placement
- Limited anatomical access
- Limited visualization and sensing
- Challenging robotic motion

Today's Single-Port



Decoupled Motion

9 degrees of freedom per arm through a single incision enables

- Simple and flexible incision placement
- Complete anatomical access
- 360 degree visualization
- Surgeon equivalent robotic motion



The Vicarious Surgical Benefit

Hospital Economics

12 Hour Shift Hospital Contribution⁵

	Multi-Port	Vicarious Surgical
Revenue	\$39,305	\$55,027
OR Costs	\$32,430	\$32,844
Material Costs	\$15,485	\$15,946
Outcome Costs	\$1,530	\$-
Total Contribution	-\$10,139	\$6,237

Advanced Sensing & Visualization

Instrumented to Support a Future of AI Automation¹³



Camera Cleans Itself

Instrument Arms:

- 56 Force and Position Sensors
- 2x Accelerometers

AI Ready:

- LIDAR ready
- Multi-modal fluorescent imaging automated tissue


Camera:

- 2x 9mm 12MP image sensors
- 12mm Intra-camera distance powerful depth tracker
- 2x 3 axis encoder
- 6-axis inertial measurement unit
- Temperature



Positioned for AI Automated Surgery

Foundational technology enables future for
advanced surgery.




Highest Quality Data Capture

28 force and position sensors and 3 axis accelerometer per arm, two 9mm 12MP image sensors with depth tracking, LIDAR-ready, temperature probe. Full surgeon input and attention tracking.



Learning From the Best

Collecting (and compressing) over 1 GB of data per second, every surgeon conducted on RBOT system gives us data to train our model.




AI Assisted Surgery¹³

Beginning with intra-operative alerts and guidance, progressing towards simple automated surgical tasks, these features will be enabled once sufficient data is collected on market.



Automated Surgery¹³

Starting with AI-supervised surgeon-operated, and moving to surgeon-supervised AI-operated over time.





First Generation Architecture

Da Vinci by Intuitive



58

MINUTES
DOWNTIME⁵

-\$10K

HOSPITAL PROFIT
PER SHIFT⁵

4%

MARKET
PENETRATION¹

>\$200B

MARKET CAP
FOR ISRG⁶

HCA

LARGEST
CUSTOMER

VICARIOUS SURGICAL INVESTOR PRESENTATION MARCH 2025

Next Generation Architecture

Vera by Vicarious



19

MINUTES
DOWNTIME⁵

+\$6K

HOSPITAL PROFIT
PER SHIFT⁵

2025

ENTERING
HUMANS

<\$100M

MARKET CAP⁶

HCA

INVESTOR & COMMITED PARTNER +
BACKED BY BILL GATES



Prepared for Successful Commercial Launch

Laying the foundation with top hospital system partnerships.



1
KEY PARTNER &
INVESTOR



6
HOSPITAL SYSTEM
PARTNERS

 **University
Hospitals**

 **Intermountain
Health**



>250
HOSPITALS

PLUS AN
ADDITIONAL
200 SURGERY
CENTERS



>1,000
SURGEONS

SUBSTANTIAL
POTENTIAL USER
BASE ACROSS
OUR PARTNERS
ALONE!





Quick Cadence of Significant Development

After 4,000 days of development, we will be filing for human use in just 150 days.



MID
2025

- Regulatory submission for First Human Use



LATE
2025

- First Human Use Cases Start
- Up to 5 patients treated



LATE
2026


- FDA De Novo Filing
- Ventral Hernia Repair Indication



Indication Pathway^{1,2}

45 Million
ABDOMINAL PROCEDURES
ADDRESSABLE BY
VICARIOUS SURGICAL

VALUE OF INITIAL MARKET
\$150 Billion





Process in a Complex Program

New Leadership Has Brought a Foundation of Process to Vicarious Surgical

People	Process	Execution
The Right Team for Execution  HARDWARE LISA FUTATO  CLINICAL AND REGULATORY MIKE TRICOLI  SOFTWARE TODD STORCH  QUALITY JAI PUAL  ELECTRICAL DAVID BONYUET  PROGRAM MANAGEMENT JAY THERRIAULT  OPERATIONS MIKE VARIEUR 	Industry Leading Processes and Standards Modeled and adapted from leading robotic and medical device companies - cut for easy collaboration and ready for regulatory approval Supply Chain: Ready for scale, focused on reliability and cost • Integrated supply chain built out and ready for scale • Netsuite ERP system implimented Quality Management System: Leading eQMS ready for production • Model from leading standards and ready for regulatory approval Agile Process: • Rigorous cross-functional program management process • “Tiger Team” approach for accelerated challenge resolution	Continue to Drive Progress Engineering: Vera 1.0 designed and produced • Progress on first indication with multiple indications preapring to launch over next 4 years. Commercial: 7 Major Hospital Systems • Over 450 total facilities ready for addoption on commercial launch Financial: Under budget for past 4 quarters • Disciplined execution against strategy, and ready to bolster balance sheet with financing Manufacturing: Full clean room production • Internal capacity scaling to 200 robotic arms per month with further expansion upon demand Program Management: • Rigorous cross-functional program overview process • “Tiger Team” approach for accelerated challenge resolution



Board and Executive Leadership

Seasoned Investors²¹



BOARD DIRECTOR
**VICTORIA
CARR-BRENDEL**
  
President of Sonova Group



BOARD DIRECTOR
RANDY CLARK
 



BOARD DIRECTOR
RIC FULOP




CO-FOUNDER, CHIEF MEDICAL OFFICER
BARRY GREENE




BOARD DIRECTOR
DAVID HO
  
Noted HIV/AIDS Researcher;
Time "Man of the Year"



Bill Gates



khosla ventures

AME CLOUD
VENTURES



BOARD DIRECTOR
BEVERLY HUSS
  
President of Qool



CO-FOUNDER, CHIEF TECHNOLOGY OFFICER,
AND BOARD DIRECTOR
SAMMY KHALIFA
 



CHIEF FINANCIAL OFFICER
SARAH ROMANO
  



CO-FOUNDER, CHIEF EXECUTIVE OFFICER,
AND BOARD DIRECTOR
ADAM SACHS
 



BOARD DIRECTOR
DONALD TANG
  



Thank You

78 Fourth Avenue
Waltham, MA, 02451

vicarioussurgical.com
+1.617.868.1700



Sources

1. VS ESTIMATES FROM DATA SOURCED FROM LSI MARKET SIZE ANALYSIS 2022 DATA AND PUBLIC FILINGS. ASSUMES \$3,319 REVENUE PER PROCEDURE CURRENTLY REALIZED BY LEGACY ROBOTIC COMPANY.
2. VS ESTIMATES FROM 2022 LSI MARKET DATA.
3. INCISIONAL COMPLICATIONS DEFINED AS OCCURRENCE OF POST-OPERATIVE HERNIA. BASED ON VICARIOUS SURGICAL EXTRAPOLATION OF DATA FROM VARIOUS STUDIES: (A) HERNANDEZ-GRANADOS P ET AL, INCISIONAL HERNIA PREVENTION AND USE OF MESH, A NARRATIVE REVIEW, 2018. AND (B) MARKS JM ET AL, SINGLE INCISION LAPAROSCOPIC CHOLECYSTECTOMY IS ASSOCIATED WITH IMPROVED COSMESIS SCORING AT THE COST OF SIGNIFICANTLY HIGHER HERNIA RATES, 2013
4. PRESENTED FOR ILLUSTRATIVE PURPOSES ONLY AND REPRESENTS ESTIMATED INCISIONAL COMPLICATION RATE BASED ON EXTRAPOLATION OF COMPLICATION RATE DATA OBSERVED IN STUDIES OF POST-OPERATIVE HERNIAS IN INCISIONS MADE USING MULTI-PORT, SINGLE-PORT AND OPEN SURGERY PROCEDURES. THIS DATA IS NOT BASED ON AND DOES NOT REFLECT CLINICAL TRIAL OR OTHER DATA OBSERVED IN PROCEDURES USING THE VICARIOUS SURGICAL SYSTEM. ACTUAL INCISION COMPLICATION RATES AND OTHER SAFETY DATA OBSERVED IN CLINICAL TRIALS OF THE VICARIOUS SURGICAL SYSTEM MAY VARY SIGNIFICANTLY.
5. BASED ON VICARIOUS SURGICAL INTERNAL ANALYSIS
6. BASED ON PUBLIC FILINGS
7. ISRG 2024 10-K AND ANNUAL REPORT
8. ISRG MATURING CLINICAL EVIDENCE META-ANALYSIS 2010-2020
9. ABOU ZEINAB M, RAMOS R, FERGUSON EL, OKHAWERE KE, IARAJULI T, WILDER S, CALVO RS, CHAVALI JS, SAINI I, DE LA ROSA RS, NGUYEN J, CRIVELLARO S, ROGERS C, STIFELMAN M, AHMED M, BADANI K, KAOUK J. SINGLE PORT VERSUS MULTI-PORT ROBOT-ASSISTED SIMPLE PROSTATECTOMY: A MULTI-INSTITUTIONAL STUDY FROM THE SINGLE-PORT ADVANCED RESEARCH CONSORTIUM (SPARC). UROLOGY. 2023 JUN;176:94-101. DOI: 10.1016/J.UROLOGY.2023.03.022. EPUB 2023 MAR 29. PMID: 37001822
10. 2021 VOLUME BY MODALITY FROM SINGLE HOSPITAL SYSTEM COE PARTNERS
11. HO C, TSAKONAS E, TRAN K, ET AL. ROBOT-ASSISTED SURGERY COMPARED WITH OPEN SURGERY AND LAPAROSCOPIC SURGERY: CLINICAL EFFECTIVENESS AND ECONOMIC ANALYSES [INTERNET]. OTTAWA (ON): CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH; 2011 SEP. (CADTH TECHNOLOGY REPORT, NO. 137.) 6, HEALTH SERVICES IMPACT.
12. ECKHOFF, JENNIFER A1,2; MÜLLER, DOLORES T2; BRUNNER, STEFANIE N2; FUCHS, HANS F2; MEIRELES, OZANAN R1. DO THE COSTS OF ROBOTIC SURGERY PRESENT AN INSURMOUNTABLE OBSTACLE? A NARRATIVE REVIEW. INTERNATIONAL JOURNAL OF ABDOMINAL WALL AND HERNIA SURGERY 6(2):P 71-76, APR
13. FEATURES EXPECTED AFTER INITIAL LAUNCH AND NECESSARY REGULATORY AUTHORIZATION. AUTOMATED PATIENT PROTECTION IS VICARIOUS SURGICAL’S TERM FOR A SET OF FUTURE FEATURES LEVERAGING THE ARCHITECTURE OF THE VICARIOUS SURGICAL PLATFORM DESIGNED TO ENHANCE PATIENT SAFETY.
14. DHARAP SB, BARBANIYA P, NAVGALE S. INCIDENCE AND RISK FACTORS OF POSTOPERATIVE COMPLICATIONS IN GENERAL SURGERY PATIENTS. CUREUS. 2022 NOV 1;14(11):E30975. DOI: 10.7759/CUREUS.30975. PMID: 36465229; PMCID: PMC9714582.
15. VAN SILFHOUT L, LEENDERS LAM, HEISTERKAMP J, IBELINGS MS; VENTRAL HERNIA GROUP TILBURG. RECURRENT INCISIONAL HERNIA REPAIR: SURGICAL OUTCOMES IN CORRELATION WITH BODY-MASS INDEX. HERNIA. 2021 FEB;25(1):77-83. DOI: 10.1007/S10029-020-02320-5. EPUB 2020 NOV 16. PMID: 33200326.
16. JOHNSON & JOHNSON INNOVATION (FEBRUARY 2021). POST-OP GASTROINTESTINAL LEAKS: A SIGNIFICANT MEDICAL PROBLEM - COLLABORATION WITH HARVARD CATALYST TO INVESTIGATE NOVEL SOLUTIONS TO IDENTIFY, DETECT, AND PREVENT POST SURGERY GI LEAKS. SLIDE 5
17. IBEANU OA, CHESSON RR, ECHOLS KT, NIEVES M, BUSANGU F, NOLAN TE. URINARY TRACT INJURY DURING HYSTERECTOMY BASED ON UNIVERSAL CYSTOSCOPY. OBSTET GYNECOL. 2009 JAN;113(1):6-10. DOI: 10.1097/AOG.0B013E31818F6219. PMID: 19104353.
18. MCCARUS SD, SHORTRIDGE EF, KIMURA T, FENG Q, HAN W, JIANG B. LONG-TERM ECONOMIC OUTCOMES OF URETERAL INJURY IN THE UNITED STATES. CURR MED RES OPIN. 2024 FEB;40(2):325-333. DOI: 10.1080/03007995.2023.2283204. EPUB 2024 JAN 24. PMID: 37961772.
19. CHART BASED ON VS ESTIMATES AND CALCULATIONS, CABLE BREAKING POINT IS APPROXIMATED. FRIEDMAN DC, LENDVAY TS, HANNAFORD B. INSTRUMENT FAILURES FOR THE DA VINCI SURGICAL SYSTEM: A FOOD AND DRUG ADMINISTRATION MAUDE DATABASE STUDY. SURG ENDOSC. 2013 MAY; 27(5):1503-8. DOI: 10.1007/S00484-012-2659-8. EPUB 2012 DEC 14. PMID: 23242487. BORDEN LS JR, KOZLOWSKI PM, PORTER CR, CORMAN JM. MECHANICAL FAILURE RATE OF DA VINCI ROBOTIC SYSTEM. CAN J UROL. 2007 APR;14(2):3499-501. PMID: 17466155
20. MANUFACTURING DATA AND VS ESTIMATES FROM PUBLIC FILINGS
21. PRESENTED SOLELY FOR THE PURPOSE OF ILLUSTRATING THE COMPANY’S CORPORATE HISTORY AS IT RELATES TO INVESTMENT AND THE CURRENT STOCKHOLDER BASE, AND DOES NOT IN ALL CASES REFLECT THE COMPANY’S PRINCIPAL STOCKHOLDERS. WE MAKE NO REPRESENTATION AS TO SUCH INVESTORS’ CONTINUED INVESTMENT IN THE COMPANY IN THE FUTURE OR THEIR PARTICIPATION IN ANY SECURITIES OFFERING BY THE COMPANY